Since the launch of its GlyCLICK® site-specific antibody labeling technology in 2017, Genovis has continuously expanded its offering within the antibody conjugation market. This has gained broad adoption across multiple areas of research, including antibody development, preclinical imaging, and ADCs. Particularly in recent years, the ADC market has experienced rapid growth, with pharmaceutical companies actively seeking new and improved technologies to attach payloads to antibodies in the creation of next-generation ADCs.

“We are excited to deepen our collaboration with Thermo Fisher Scientific, “said Fredrik Olsson, CEO at Genovis. “Expanding the license to therapeutic applications allows our technology to support the advancement of promising ADC candidates into clinical development and, ultimately, the market.”

With this expanded collaboration, Genovis is now well-positioned to support its customers across the entire ADC development pipeline—from early discovery to therapeutic manufacturing—unlocking new value in a high-growth market.

More about GlyCLICK®
GlyCLICK is based on a technology platform in which Genovis’ unique enzyme GlycINATOR is combined with SiteClick™ technology from Thermo Fisher Scientific. GlyCLICK is a platform for labeling antibodies at the same site (site specific) each time, with high reproducibility and with a broad range of applications. GlyCLICK can be used to label antibodies with markers for microscopy, preclinical imaging or to activate the antibody for labeling in chemotherapy. Labeling antibodies with various markers is a technique used in several areas of pharmaceutical research and development. Using the GlyCLICK technology platform, the label always attaches at precisely the same site and it is possible to label with many different markers, which makes the technology both versatile and scalable. For more information about GlyCLICK (www.genovis.com/glyclick).